Safety, Tolerability, Immunogenicity, and Antitumor Activity of GEN-009 Adjuvanted Vaccine

NCT03633110 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Cutaneous Melanoma
Non-small Cell Lung Cancer
Squamous Cell Carcinoma of the Head and Neck
Urothelial Carcinoma
Renal Cell Carcinoma

Interventions

BIOLOGICAL: GEN-009 Adjuvanted Vaccine
DRUG: Nivolumab
DRUG: Pembrolizumab

Sponsor

Genocea Biosciences, Inc.